Stock - my posts are limited for the day so I might not be able to respond again until tomorrow. My opinion is that this is the last submission before approval. One important thing to keep in mind is that the PPS is no indication of what the FDA decision will be. The proof of that is that if it was indicative we would either be under a dime or over two bucks for sure. I believe that the new review team took 2 months to look over all the prior submissions and concluded with 18 questions plus a radiologist review. When all this was resubmitted the FDA only needed to cross the T's and dot the I's. The fast track program allows Dean to communicate by phone and resolve issues in a fashion that would expedite the process. If the review was submitted and accepted then I personally see no reason that we should not get approval this time. This is only my opinion and I am sure as many posters on board believe that much of the PPS deterioration has been because of PPM shares and shorters taken center stage. The day is approaching quickly and I would not be at all surprised to see the PPS climb as we get closer to the targeted date.
News 
Market Data 
Discover 
AI
